INDGN2024-07-012024-09-30 INDGN2024-07-012024-09-30 INDGN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member INDGN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member INDGN2024-09-30 INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue03Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue04Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue03Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue04Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults03Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults04Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults03Member INDGN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults04Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets03Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets04Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-09-30in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDGN2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544172 INDGN NOTLISTED Indegene Limited Equity 2024-04-01 2025-03-31 2024-10-28 2024-10-22 INR Millions Half yearly 18:10:00 18:50:00 2024-10-28 2024-10-28 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Consolidated 6868000000.00 214000000.00 7082000000.00 0.00 0.00 0.00 4420000000.00 40000000.00 194000000.00 1187000000.00 5841000000.00 1241000000.00 0.00 1241000000.00 363000000.00 -39000000.00 324000000.00 0.00 917000000.00 0.00 0.00 0.00 0.00 917000000.00 106000000.00 1023000000.00 917000000.00 0.00 1023000000.00 0.00 478000000.00 2 3.84 3.80 0.00 0.00 3.84 3.80 EPS is not annualized for the quarter and six months ended 30 September 2024. Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2024 (All amounts in INR millions, except share data and where otherwise stated) 1. The above Consolidated Financial Results of the Group have been prepared in accordance with Indian Accounting Standards ( Ind AS ) 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ( the regulations ). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. ^ in the financial information denote amounts less than INR 0.50 million. 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 October 2024. The statutory auditors have performed an limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2024 and have issued an unmodified review report on the same. 3. The Consolidated Financial Results for the quarter and six months ended 30 September 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 4. During the six months ended 30 September 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of INR 2 each at an issue price of INR 452 per share, comprising fresh issue of 16,833,818 shares aggregating to INR 7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR 10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024.The Company was not mandatorily required to prepare and publish results for the quarter and six months ended 30 September 2023 in accordance with the regulations. 5. On 22 March 2024, the Group had obtained control of Trilogy Writing & Consulting GmbH (‘Trilogy GmbH’), by acquiring 100% of its shares. The acquisition was consummated for a consideration of INR 1,508 which includes earnout payment of INR 489. The contingent consideration is based on the performance of Trilogy GmbH during the fiscal year beginning 01 April 2024 and ending 31 March 2025 and range of contingent consideration payable is between Nil to INR 1,268. The Group has concluded that the acquired set is a business. The fair value of net assets acquired on the acquisition date as a part of the transaction amounted to INR 242. The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to INR 328 and goodwill aggregating to INR 938. Note 6 is presented in Asset Liabilities sheet Multi segment 2024-04-01 2024-09-30 Unaudited Consolidated 13633000000.00 439000000.00 14072000000.00 0.00 0.00 0.00 8863000000.00 157000000.00 395000000.00 2220000000.00 11635000000.00 2437000000.00 0.00 2437000000.00 715000000.00 -72000000.00 643000000.00 0.00 1794000000.00 0.00 0.00 0.00 0.00 1794000000.00 98000000.00 1892000000.00 1794000000.00 0.00 1892000000.00 0.00 478000000.00 2 7.63 7.56 0.00 0.00 7.63 7.56 Other Expenses 1187000000.00 Other Expenses 2220000000.00 0.00 1107000000.00 0.00 0.00 3385000000.00 1828000000.00 0.00 0.00 0.00 0.00 0.00 0.00 117000000.00 117000000.00 788000000.00 121000000.00 7346000000.00 0.00 9169000000.00 7048000000.00 3119000000.00 2378000000.00 140000000.00 102000000.00 21956000000.00 235000000.00 704000000.00 22895000000.00 0.00 0.00 30241000000.00 478000000.00 23122000000.00 23600000000.00 23600000000.00 0.00 0.00 1047000000.00 1047000000.00 495000000.00 0.00 0.00 0.00 1542000000.00 0.00 870000000.00 1878000000.00 2748000000.00 1539000000.00 687000000.00 125000000.00 5099000000.00 0.00 0.00 6641000000.00 30241000000.00 Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2024 (Contd.) 6. Exceptional items: On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Group's commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of INR 5,347. The contingent consideration is based on the performance of Cult during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between INR Nil to INR 3,040. Cult Health LLC is part of Omnichannel Activation segment. The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of INR 935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the quarter and year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of INR 911. The impairment charge had been recognized as an exceptional item during the quarter and year ended 31 March 2024. Notes to Assets and Liabilites: a. Property, plant and equipment includes Right-of-use assets of INR 813. b. Other non-current asset includes Non-current tax assets of INR 45 and Other non-current asset of INR 76 aggregating to INR 121. c. Trade receivables, current includes Unbilled revenue of INR 1130. d. Other non current financial liabilities includes lease liabilities of INR 589 and other financial liabilities of INR 458 aggregating to INR 1047. e. Trade payables, current comprises of total outstanding dues of micro enterprises and small enterprises of INR 24 and total outstanding dues of creditors other than micro enterprises and small enterprises of INR 846. f. Other current financial liabilities includes lease liabilities INR 292 and other financial liabilities of INR 1586 aggregating to INR 1878. Enterprise Commercial Solutions 3863000000.00 Enterprise Medical Solutions 1977000000.00 Omnichannel Activation 798000000.00 Others* 230000000.00 Enterprise Commercial Solutions 7612000000.00 Enterprise Medical Solutions 3866000000.00 Omnichannel Activation 1621000000.00 Others* 534000000.00 6868000000.00 13633000000.00 6868000000.00 13633000000.00 Enterprise Commercial Solutions 797000000.00 Enterprise Medical Solutions 521000000.00 Omnichannel Activation 90000000.00 Others* -95000000.00 Enterprise Commercial Solutions 1666000000.00 Enterprise Medical Solutions 962000000.00 Omnichannel Activation 178000000.00 Others* -166000000.00 1313000000.00 2640000000.00 40000000.00 157000000.00 32000000.00 *Others mainly comprises of consultancy and clinical business. Operating Segment - The Segment results of the Group has been prepared in accordance with AS-108 on Operating Segments . The Group has identified business segments (industry practice) as reportable segments. The business segments comprise: 1) Enterprise Medical Solutions, 2) Enterprise Commercial Solutions, 3) Omnichannel Activation. Notes on Segment information: Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Group's chief operating decision maker is the Chief Executive Officer and Executive Director. Assets and liabilities used in the Group’s business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous. Other unallocable expenditure net of unallocable income for the quarter ended 30 September 2024 includes depreciation and amortisation expense (INR 194) and unallocable expenses (INR 52) net of other income (INR 214). *Other unallocable expenditure net of unallocable income for the six months ended 30 September 2024 includes depreciation and amortisation expense (INR 395) and unallocable expenses (INR 90) net of other income (INR 439). Statement of Cash Flow includes following aggregations: 1.Cash flows from Operating Activities: Other adjustments to reconcile profit (loss) includes a. Net gain on disposal / fair valuation of investments (INR 112) b. Liability no longer required reversed (INR 6) c. Expected credit loss on trade receivables and advances INR 8 d. Bad debt expense written off INR 8 2.Cash flows from Investing Activities Other Inflow Outflows of cash includes a. Purchase of investments accounted using FVTPL (INR 13034) b. Proceeds from redemption of investments INR 11942 c. Investments in fixed deposits (INR 7927) d. Redemption or maturity of fixed deposit INR 5574 3. Cash flows from Financing Activities Proceeds from issuing shares is net of share issue expenses 46000000.00 1241000000.00 2437000000.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 144000000.00 0.00 -521000000.00 0.00 673000000.00 0.00 0.00 0.00 0.00 0.00 0.00 -624000000.00 0.00 395000000.00 0.00 59000000.00 0.00 0.00 0.00 34000000.00 0.00 282000000.00 90000000.00 0.00 0.00 0.00 -102000000.00 0.00 0.00 -134000000.00 2303000000.00 0.00 0.00 0.00 950000000.00 0.00 1353000000.00 0.00 0.00 0.00 16000000.00 0.00 0.00 0.00 0.00 0.00 46000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 279000000.00 0.00 -3445000000.00 0.00 -3228000000.00 0.00 0.00 7296000000.00 0.00 0.00 0.00 0.00 0.00 0.00 3989000000.00 0.00 141000000.00 0.00 102000000.00 0.00 0.00 3064000000.00 1189000000.00 44000000.00 1233000000.00 1886000000.00 3119000000.00 Remeasurement of defined benefit obligation -8000000.00 Remeasurement of defined benefit obligation 7000000.00 -8000000.00 7000000.00 -2000000.00 2000000.00 Exchange differences on translating the financial statements of foreign operations 112000000.00 Exchange differences on translating the financial statements of foreign operations 93000000.00 112000000.00 93000000.00 0.00 0.00